Sapid Agency in Juxta-Epithelial Perioral Fibrosclerotic Remodeling Arecoline-Containing Chewable Formulation Tar-Exposed Persons and Eubiotic Persons

<p>Oral submucous fibrosis (OSMF) is a chronic debilitating disease that is progressive in nature and has significant malignant potential. The disease mainly involves the lamina propria and may later go on to involve the deeper tissues of the submucosa in its advanced stages eventually leading to loss of its fibro-elasticity. This entity was first described in 600 B.C. by Sushruta by the name Vidari. The disease was noted by Schwartz in the year 1952 in five Indian females residing in Kenya. He was the one who coined the term Atrophia idiopathica (trophica) mucosae oris. However the true understanding of the condition came several decades later when a Danish pathologist Jens Pindborg studied the disease in his extensive travel expeditions and very comprehensively laid out the numerous facets of the disease. J. Pindborg has defined OSMF as an insidious chronic disease affecting any part of the oral cavity and sometimes the pharynx. Although occasionally preceded by and/or associated with vesicle formation it is always associated with a juxta- epithelial inflammatory reaction followed by a fibroelastic change of the lamina propria with epithelial atrophy leading to stiffness of the oral mucosa and causing trismus and inability to eat. </p>